<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Novel Once-Daily Extended-Release Tacrolimus Versus Twice-Daily Tacrolimus in De Novo Kidney Transplant Recipients: Two-Year Results of Phase 3, Double-Blind, Randomized Trial</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author role="corresp">
							<persName><roleName>MD</roleName><forename type="first">Lionel</forename><surname>Rostaing</surname></persName>
							<email>rostaing.l@chu-toulouse.fr</email>
							<affiliation key="aff0">
								<orgName type="department">DNTO</orgName>
								<orgName type="institution">CHU Rangueil</orgName>
								<address>
									<addrLine>1 avenue Jean Poulhes</addrLine>
									<postCode>50032, 31400</postCode>
									<settlement>Tou-louse Cédex 9</settlement>
									<region>TSA</region>
									<country key="FR">France</country>
								</address>
							</affiliation>
							<affiliation key="aff0">
								<orgName type="department">DNTO</orgName>
								<orgName type="institution">CHU Rangueil</orgName>
								<address>
									<addrLine>1 avenue Jean Poulhes</addrLine>
									<postCode>50032, 31400</postCode>
									<settlement>Tou-louse Cédex 9</settlement>
									<region>TSA</region>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Suphamai</forename><surname>Bunnapradist</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">DNTO</orgName>
								<orgName type="institution">CHU Rangueil</orgName>
								<address>
									<addrLine>1 avenue Jean Poulhes</addrLine>
									<postCode>50032, 31400</postCode>
									<settlement>Tou-louse Cédex 9</settlement>
									<region>TSA</region>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Josep</forename><forename type="middle">M</forename><surname>Grinyo ´</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">DNTO</orgName>
								<orgName type="institution">CHU Rangueil</orgName>
								<address>
									<addrLine>1 avenue Jean Poulhes</addrLine>
									<postCode>50032, 31400</postCode>
									<settlement>Tou-louse Cédex 9</settlement>
									<region>TSA</region>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Kazimierz</forename><surname>Ciechanowski</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">DNTO</orgName>
								<orgName type="institution">CHU Rangueil</orgName>
								<address>
									<addrLine>1 avenue Jean Poulhes</addrLine>
									<postCode>50032, 31400</postCode>
									<settlement>Tou-louse Cédex 9</settlement>
									<region>TSA</region>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Jason</forename><forename type="middle">E</forename><surname>Denny</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">DNTO</orgName>
								<orgName type="institution">CHU Rangueil</orgName>
								<address>
									<addrLine>1 avenue Jean Poulhes</addrLine>
									<postCode>50032, 31400</postCode>
									<settlement>Tou-louse Cédex 9</settlement>
									<region>TSA</region>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Helio</forename><surname>Tedesco</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">DNTO</orgName>
								<orgName type="institution">CHU Rangueil</orgName>
								<address>
									<addrLine>1 avenue Jean Poulhes</addrLine>
									<postCode>50032, 31400</postCode>
									<settlement>Tou-louse Cédex 9</settlement>
									<region>TSA</region>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Silva</forename><surname>Jr</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">DNTO</orgName>
								<orgName type="institution">CHU Rangueil</orgName>
								<address>
									<addrLine>1 avenue Jean Poulhes</addrLine>
									<postCode>50032, 31400</postCode>
									<settlement>Tou-louse Cédex 9</settlement>
									<region>TSA</region>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Klemens</forename><surname>Budde</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">DNTO</orgName>
								<orgName type="institution">CHU Rangueil</orgName>
								<address>
									<addrLine>1 avenue Jean Poulhes</addrLine>
									<postCode>50032, 31400</postCode>
									<settlement>Tou-louse Cédex 9</settlement>
									<region>TSA</region>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Novel Once-Daily Extended-Release Tacrolimus Versus Twice-Daily Tacrolimus in De Novo Kidney Transplant Recipients: Two-Year Results of Phase 3, Double-Blind, Randomized Trial</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="MD5">ADC286A30991117529A44C7FD5F3046C</idno>
					<idno type="DOI">10.1053/j.ajkd.2015.10.024</idno>
					<note type="submission">Received May 11, 2015. Accepted in revised form October 16, 2015. Originally published online December 22, 2015.</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:22+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>Immunosuppression</term>
					<term>tacrolimus</term>
					<term>kidney transplantation</term>
					<term>extended-release</term>
					<term>formulation</term>
					<term>bioavailability</term>
					<term>efficacy</term>
					<term>treatment failure</term>
					<term>safety</term>
					<term>biopsy-proven acute rejection</term>
					<term>Envarsus</term>
					<term>pill burden</term>
					<term>transplant recipient</term>
					<term>end-stage renal disease (ESRD)</term>
					<term>randomized controlled trial (RCT)</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Background: 1-year data from this trial showed the noninferiority of a novel once-daily extended-release tacrolimus (LCPT; Envarsus XR) to immediate-release tacrolimus (IR-Tac) twice daily after kidney transplantation.</s></p><p><s>Study Design: Final 24-month analysis of a 2-armed, parallel-group, randomized, double-blind, doubledummy, multicenter, phase 3 trial.</s></p><p><s>Setting &amp; Participants: 543 de novo kidney recipients randomly assigned to LCPT (n 5 268) or IR-Tac (n 5 275); 507 (93.4%) completed the 24-month study.</s></p><p><s>Intervention: LCPT tablets once daily at 0.17 mg/kg/d or IR-Tac twice daily at 0.1 mg/kg/d; subsequent doses were adjusted to maintain target trough ranges (first 30 days, 6-11 ng/mL; thereafter, 4-11 ng/mL).</s><s>The intervention was 24 months; the study was double blinded for the entirety.</s></p><p><s>Outcomes &amp; Measurements: Treatment failure (death, transplant failure, biopsy-proven acute rejection, or loss to follow up) within 24 months.</s><s>Safety end points included adverse events, serious adverse events, newonset diabetes, kidney function, opportunistic infections, and malignancies.</s><s>Pharmacokinetic measures included total daily dose (TDD) of study drugs and tacrolimus trough levels.</s></p><p><s>Results: 24-month treatment failure was LCPT, 23.1%; IR-Tac, 27.3% (treatment difference, 24.14% [95% CI, 211.38% to 13.17%], well below the 110% noninferiority criterion defined for the primary 12-month end point).</s><s>Subgroup analyses showed fewer treatment failures for LCPT versus IR-Tac among black, older, and female recipients.</s><s>Safety was similar between groups.</s><s>From month 1, TDD was lower for LCPT; the difference increased over time.</s><s>At month 24, mean TDD for LCPT was 24% lower than for the IR-Tac group (P , 0.001), but troughs were similar (means at 24 months: LCPT, 5.47 6 0.17 ng/mL; IR-Tac, 5.8 6 0.30 ng/mL; P 5 0.4).</s></p><p><s>Limitations: Trial participant eligibility criteria may limit the generalizability of results to the global population of de novo kidney transplant recipients.</s></p><p><s>Conclusions: Results suggest that once-daily LCPT in de novo kidney transplantation has comparable efficacy and safety profile to that of IR-Tac.</s><s>Lower TDD reflects LCPT's improved bioavailability and absorption.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>T acrolimus is overwhelmingly used as an immunosuppressant in kidney transplantation, both early posttransplantation and as part of long-term maintenance regimens. <ref type="bibr" target="#b19">1</ref></s><s>While highly effective in preventing acute transplant rejection, tacrolimus has several limitations, including a narrow therapeutic window (necessitating drug monitoring and individual dose titration <ref type="bibr" target="#b20">2</ref> ), interindividual variation in absorption, and low bioavailability (17% 6 10%) of the currently widely used immediate-release tacrolimus From the <ref type="bibr" target="#b19">1</ref> University Hospital Toulouse-Rangueil, Toulouse, France; 2 David Geffen School of Medicine at UCLA, Los Angeles, CA; 3 Hospital Universitari de Bellvitge, Catalunya, Spain; <ref type="bibr" target="#b21">4</ref> Pomeranian Medical University, Szczecin, Poland; <ref type="bibr" target="#b23">5</ref> Henry Ford Hospital, Detroit, MI; <ref type="bibr" target="#b24">6</ref> Hospital do Rim e Hipertensao, Sao Paulo, Brazil; and <ref type="bibr" target="#b25">7</ref> Department of Nephrology, Charité Universitätsmedizin, Berlin, Germany.</s></p><p><s>6]<ref type="bibr" target="#b25">[7]</ref> Additionally, the twice-daily formulation adds further pill burden to a patient population already encumbered with taking many long-term medications.</s><s>Multiple daily drug dosing is associated with increased risk for nonadherence <ref type="bibr" target="#b26">[8]</ref><ref type="bibr" target="#b27">[9]</ref><ref type="bibr" target="#b28">[10]</ref> ; this may result in acute rejection <ref type="bibr" target="#b29">11</ref> and, in severe cases, transplant failure. <ref type="bibr" target="#b30">12</ref></s><s>he medication LCP-Tacro (LCPT; Envarsus XR; Veloxis Pharmaceuticals) is an extended-release tablet formulation of tacrolimus with once-daily dosing that has been developed using a proprietary MeltDose drug delivery technology (Veloxis Pharmaceuticals), distinguishing LCPT from other oncedaily extended-release tacrolimus products (eg, Astagraf XL).</s><s>The MeltDose technology decreases a drug's particle size to the smallest possible units as single molecules (ie, a "solid solution"). <ref type="bibr">13</ref></s><s>Drug particle size critically affects drug dissolution and absorption; if particle size is smaller, the surface area of the drug increases and the drug will be dissolved more quickly, resulting in better absorption. <ref type="bibr">14</ref></s><s>Results of the MeltDose technology are increased absorption and bioavailability associated with LCPT tablets compared with other extended-release and IR tacrolimus formulations currently available.</s><s>Phase 1 and phase 2 trials confirmed that LCPT enables broader absorption throughout the gastrointestinal tract and sustains consistent tacrolimus concentrations. <ref type="bibr" target="#b31">15</ref></s><s>In addition, LCPT showed a lack of diurnal variability <ref type="bibr" target="#b33">16</ref> common with other formulations. <ref type="bibr">3,</ref><ref type="bibr" target="#b34">17</ref></s><s>hase 2 trials of de novo and stable kidney <ref type="bibr" target="#b35">18,</ref><ref type="bibr" target="#b36">19</ref> and liver recipients <ref type="bibr" target="#b37">20,</ref><ref type="bibr" target="#b38">21</ref> showed a steadier and more consistent concentration-time profile over 24 hours, with reduced peak and peak-to-trough fluctuations for LCPT compared to IR-Tac, increased bioavailability of w30%, and comparable efficacy and safety profiles.</s><s>A robust correlation between the area under the curve at 24 hours and the minimum concentration was also shown, indicating that therapeutic drug monitoring of minimum concentration as a measure of tacrolimus exposure can be applied to LCPT.</s><s>A phase 3 conversion trial showed that LCPT had noninferior efficacy and comparable safety profile to IR-Tac, with lower doses (w20% lower than IR-Tac overall and 30% lower in white patients) of LCPT. <ref type="bibr" target="#b39">22</ref></s><s>reviously, the 12-month primary efficacy and safety outcomes were reported from this phase 3 double-blind double-dummy trial of de novo kidney transplant recipients randomly assigned to LCPT or IR-Tac. <ref type="bibr" target="#b40">23</ref></s><s>Here, the prespecified blinded efficacy and safety outcomes at 24 months' follow-up are reported from this same phase 3 trial.</s><s>Efficacy was also analyzed within patient subgroups (ie, females, blacks, and recipients aged $ 65 years) in order to explore the consistency of results, or lack thereof, within specific patient populations.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>METHODS</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Study Overview</head><p><s>This was a 2-armed, parallel group, prospective, randomized, double-blind, double-dummy, multicenter, 24-month, phase 3 trial.</s><s>The study design has been previously reported. <ref type="bibr" target="#b40">23</ref></s><s>Both the 1-and the 2-year analyses were a priori planned as explicitly stated in the study protocol.</s><s>The primary endpoint was based on the 1-year analysis and the 2-year analysis was the final analysis designed to assess long-term efficacy and safety outcomes; patients and investigators stayed blinded for the full 24 months.</s><s>In brief, adult de novo recipients of a living or deceased donor kidney transplant were randomly assigned to receive LCPT tablets once daily on a starting dose of 0.17 mg/kg/d or IR-Tac twice-daily (Prograf) capsules at 0.1 mg/kg/d.</s><s>Subsequent doses of each study drug were adjusted to maintain whole-blood trough concentrations within the target range of 6 to 11 ng/mL for the first 30 days, then 4 to 11 ng/mL for the rest of the study.</s><s>All patients also received a matching double-dummy placebo to maintain the blind.</s><s>All patients also received mycophenolate mofetil (1 g twice daily) or mycophenolic acid (720 mg twice daily), an interleukin 2 receptor antagonist, and corticosteroids per local practice.</s></p><p><s>Key study exclusion criteria were as follows: receipt of an organ transplant other than kidney; panel-reactive antibody .</s><s>30%; body mass index , 18 or .40</s><s>kg/m 2 ; receipt of sirolimus, everolimus, azathioprine, or cyclophosphamide within 3 months before enrollment; and abnormal laboratory values.</s></p><p><s>Health authority, ethics committee, and institutional review board approval were obtained at each participating center, and informed consent was obtained from all patients.</s><s>The study was undertaken in accordance with the ICH (International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use) Harmonized Tripartite Guidelines for Good Clinical Practice and conformed to the Declaration of Helsinki.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Study End Points</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Efficacy</head><p><s>The incidence of treatment failures (any of the following: death, transplant failure, biopsy-proven acute rejection [BPAR; Banff grade $ 1A, using Banff 2007 criteria; based on centrally read biopsies], or loss to follow-up) within 24 months after randomization was compared between LCPT and IR-Tac for the overall sample and also stratified by the following subgroups: age (,65 and $65 years), race (black or nonblack), and sex (male or female).</s></p><p><s>The incidence of each individual event (death, transplant failure, BPAR, or loss to follow-up) within 24 months after the randomization date was also assessed.</s><s>Efficacy results are reported for the overall 24-month study period and separately for the 0-to 12-month and 13-to 24-month periods.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Safety</head><p><s>Safety end points at 24 months included the following: incidence of AEs, serious AEs (SAEs), and discontinuations due to AEs; incidence of predefined potentially clinically significant laboratory values; new-onset diabetes after transplantation LCPT Versus Immediate-Release Tacrolimus Am J Kidney Dis.</s><s>2016;67(4):648-659 (NODAT); incidence of posttransplantation lymphoproliferative disorder; mean change from baseline (day 30) in estimated glomerular filtration rate (MDRD7 [Modification of Diet in Renal Disease] Study equation); change in clinical laboratory values and vital signs; incidence of opportunistic infections; and any malignancy or BK virus diseases.</s><s>As prespecified in the study protocol, NODAT analysis was restricted to patients without diabetes at baseline and patients with no medical history of diabetes, baseline fasting plasma glucose level , 126 mg/dL, no prior use of a hypoglycemic agent for diabetes conditions, no prior use of insulin for diabetes conditions, or hemoglobin A 1c level , 6.5% before transplantation.</s><s>Patients meeting the at-risk definition were considered to have NODAT if they met any of the following 4 criteria: fasting plasma glucose level $ 126 mg/dL, hemoglobin A 1c level $ 6.5% 90 days or later after randomization, new-onset oral hypoglycemic agent use, or new-onset insulin use for more than 30 days.</s><s>In general, AEs and infections were spontaneously reported by the investigator and then mapped to MedDRA (Medical Dictionary for Regulatory Activities) preferred terms.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statistical Analysis</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Sample Size Determination</head><p><s>Sample size determination was based on the 12-month primary end point.</s><s>Based on an expected treatment failure rate of 15% at 1 year, 270 patients per group were required to have 90% power to reject the null hypothesis that LCPT was inferior to IR-Tac based on a 2-sided 95% confidence interval (CI) upper bound and a 10% noninferiority margin.</s></p><p><s>The study design and vigorous 10% noninferiority margin used for the 12-month analysis were decided upon in pretrial collaboration with the US Food and Drug Administration.</s><s>Subgroup analyses were prespecified in the Statistical Analysis Plan for the study for the 12-month outcomes; the same subgroup analyses were performed at 24 months for consistency check of the 12-and 24-month data.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Analysis Method</head><p><s>The total daily dose (TDD) the day before a trough sample recorded in the case report forms was used to compute the ratio of trough value to dose for each trough sample for each patient.</s><s>The ratio was then tabulated by treatment group and time point; differences in ratios between groups at each time point were evaluated by 1-way analysis of variance with main effect of treatment.</s></p><p><s>Treatment failure within 24 months was assessed using a 2sided 95% CI for the difference (LCPT minus IR-Tac) in treatment failure rates between treatment groups.</s><s>The incidence of clinically suspected and treated acute rejection episodes and the incidence of BPAR episodes was compared between treatment groups using Fisher exact test and 2-sided 95% CI for the difference.</s><s>The 2-sided 95% CIs for the differences were calculated using the Newcombe-Wilson score method.</s><s>In addition, the association between treatment and severity grade of the first BPAR episode was assessed using Cochran-Mantel-Haenszel test for general association.</s></p><p><s>Differences between treatment groups in time-to-event distributions were evaluated using log-rank tests, displayed as Kaplan-Meier curves.</s><s>Baseline characteristics and treatment-emergent AEs were tabulated by treatment.</s><s>Change from baseline in lipid levels was compared using an analysis of covariance model with main effect of treatment and baseline as covariates.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>RESULTS</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Study Overview</head><p><s>The study was initiated on October 13, 2010.</s><s>All randomly assigned participants completed the 24-month visit by March 26, 2014, at 68 sites (United States, n 5 31; Latin America, n 5 13; Europe, n 5 15; and Asia Pacific, n 5 9).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Patient Disposition and Baseline Characteristics</head><p><s>A total of 543 patients were randomly assigned to the study drug (intention-to-treat population; LCPT, n 5 268; IR-Tac, n 5 275).</s><s>Overall, 507 (93.4%) patients completed the 24-month study period and 394 (72.6%) completed the 24-month study on study drug (LCPT, n 5 195; IR-Tac, n 5 199; Fig 1 Demographic characteristics were similar between treatment groups.</s><s>The patient population was predominately white (76.8%) and male (65.4%); mean age was 45.8 years (Table <ref type="table" target="#tab_1">1</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Immunosuppression</head><p><s>As a result of the higher starting dose for LCPT, initial TDDs were higher in patients in the LCPT group versus the IR-Tac group.</s><s>From months 1 through 12, TDDs were lower in the LCPT group, and the difference between groups increased over time.</s><s>At month 3, TDD for the LCPT group was w14% lower, and by month 12, w20% lower.</s><s>At month 24, mean TDD for the LCPT group was 24.4% lower than that for the IR-Tac group (3.</s><s>Tacrolimus trough levels were notably higher in the LCPT group compared with the IR-Tac group in the first 2 weeks after dosing; thereafter, trough levels in the 2 groups were similar (Fig <ref type="figure">2</ref>).</s><s>Although a greater proportion of LCPT (67%) versus IR-Tac (25%) patients had tacrolimus trough levels $ 6 ng/mL by day 2, <ref type="bibr" target="#b40">23</ref> the majority of patients in both treatment groups were within the post-30-day target range of 4 to 11 ng/mL from month 1.5 through month 24 (71.5%-84.5% for LCPT and 78.3%-87.0%</s><s>for IR-Tac).</s></p><p><s>Analysis of trough to dose ratio demonstrated an increasing ratio for LCPT throughout the 24 months (Fig 3 <ref type="figure">)</ref>; this reflected the improved absorption provided by the MeltDose formulation.</s><s>This is apparent over time as the dose decreases but the trough level remains stable and similar to that of IR-Tac.</s><s>Absorption (ie, bioavailability) per milligram was significantly higher in the LCPT group versus the IR-Tac group by month 12 (means for LCPT and IR-Tac of 2.3 6 0.11 and 1.6 6 0.07, respectively; P , 0.001) and month 24 (means for LCPT and IR-Tac of 2.2 6 0.11 and 1.68 6 0.07, respectively; P , 0.001).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Efficacy End Point</head><p><s>Treatment failure at 24 months was 23.1% for patients in the LCPT group and 27.3% for patients in the IR-Tac group.</s><s>The treatment difference was 24.14% (95% CI, 211.38% to 13.17%), well below the noninferiority margin of 10% that was used for the 12-month primary efficacy end point.</s><s>No statistically significant difference was observed between the LCPT and IR-Tac groups for the incidence of all-cause mortality (P 5 0.8), transplant failure (P 5 0.5), BPAR (P 5 0.8), or loss to follow-up (P 5 0.4; Table <ref type="table" target="#tab_2">2</ref>).</s></p><p><s>No statistically significant difference was observed between the 2 treatment groups in time-to-event distribution during the 24-month study period by log-rank test: treatment failure (P 5 0.3) and first episode of BPAR (P 5 0.7).</s><s>Overall patient survival was 95.9% versus 95.2% (P 5 0.7), and transplant survival was 95.8% versus 94.4% (P 5 0.4) for LCPT and IR-Tac, respectively.</s><s>Both drug groups had more treatment failures in the first versus second 12 months of the study.</s><s>In both study years, LCPT had fewer treatment failures; a larger difference between groups was seen between study years 1 and 2 compared to the first 12 months (Table <ref type="table" target="#tab_2">2</ref></s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>; Fig 4).</head><p><s>There were no statistically significant differences between the 2 treatment groups in incidence of patients with clinically suspected and treated rejections, number of BPAR episodes, or severity of the first BPAR episode (Table <ref type="table" target="#tab_3">3</ref>).</s><s>There were more acute rejection episodes in the first year compared to the second study year in both groups (Tables <ref type="table" target="#tab_3">2 and 3</ref>).</s></p><p><s>Subgroup analyses showed that the LCPT group had fewer treatment failures compared to the IR-Tac group in females, blacks, and recipients 65 years or older (Fig <ref type="figure">5</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Safety</head><p><s>Treatment-Emergent AEs Mean numbers of AEs per patient during the study were 14.3 and 14.4 for the LCPT and IR-Tac groups, respectively.</s><s>The incidence of AEs was similar between the 2 treatment groups (Table <ref type="table" target="#tab_5">4</ref>).</s><s>AEs reported Abbreviations and definitions: IR-Tac, immediate-release tacrolimus, twice-daily; LCPT, extended-release tacrolimus, once daily; PRA, panel-reactive antibody.</s></p><p><s>in the second year tended to follow the same pattern as in the first study year; however, AEs tended to be fewer for the second year of the study compared to the first 12 months (percentages of patients with $1 AE in the first vs second year were 98% vs 74% and 99% vs 70% for the LCPT and IR-Tac groups, respectively).</s></p><p><s>The majority of patients had at least 1 mild (LCPT, 92.2%; IR-Tac, 93.8%) or moderate (LCPT, 82.8%; IR-Tac, 84.7%) AE.</s><s>Eighty (29.9%) patients in the LCPT group and 95 (34.5%) in the IR-Tac group had at least 1 severe event.</s></p><p><s>The majority of events (.80%) were not suspected to be related to study drug.</s><s>However, 64.9% of patients in the LCPT group and 59.3% of patients in the IR-Tac group had at least 1 event suspected to be related to the study drug.</s></p><p><s>The proportion of patients who had AEs resulting in discontinuation from study drug and/or withdrawal from the study was similar in the treatment groups (0-12 months: 8.6% in LCPT, 9.8% in IR-Tac; 0-24 months: 11.6% in LCPT, 12.7% in IR-Tac).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Treatment-Emergent SAEs</head><p><s>In the LCPT and IR-Tac groups, 61.9% and 67.3% of patients, respectively, had treatment-emergent SAEs.</s><s>The frequency of SAEs tended to be fewer for the second year versus the first 12 months (percentages of patients with $1 SAE in the first vs second year were 53% vs 24% and 58% vs 24%, for LCPT and IR-Tac, respectively).</s></p><p><s>Twenty-four deaths (11 in LCPT [first year, 8; second year, 3] and 13 in IR-Tac [first year, 8; second year, 5]) occurred during the study.</s><s>Most causes of death were related to the cardiopulmonary system.</s><s>None of the 11 fatal SAEs in the LCPT group were suspected to be related to the study drug.</s><s>Three of the 13 patients who died in the IR-Tac group had events (sepsis) considered to be related to study drug.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Potentially Clinically Significant Laboratory Values and Kidney Function</head><p><s>No statistically significant difference was observed between treatment groups in the incidence of predefined potentially clinically significant laboratory measurements.</s><s>Abbreviations: BPAR, biopsy-proven acute rejection; CI, confidence interval; IR-Tac, immediate-release tacrolimus, twice-daily; LCPT, extended-release tacrolimus, once daily; NA, not applicable.</s><s>a Two-sided 95% CIs were calculated using Newcombe-Wilson score intervals.</s><s>For the primary efficacy end point (12-month treatment failure rate), difference between groups was assessed by a noninferiority approach with a noninferiority margin of 10%.</s><s>Laboratory results most commonly reported as an AE were anemia, hypophosphatemia, leukopenia, hyperkalemia, increased blood creatinine level, hypokalemia, hypomagnesemia, hyperglycemia, and vitamin D deficiency.</s><s>Most were mild or moderate in severity and most were not suspected to be related to study drug.</s></p><p><s>Hematology, chemistry, hepatic profile, urinalysis, vital signs, physical examination, and estimated glomerular filtration rate results had minimal change from baseline for both tacrolimus formulations (Table <ref type="table" target="#tab_5">4</ref>).</s></p><p><s>Within 24 months after randomization, 24 of 88 (27.3%) and 12 of 74 (16.2%) at-risk patients in the LCPT and IR-Tac groups, respectively, had developed NODAT (P 5 0.1).</s><s>Change from baseline in hemoglobin A 1c level was similar for both treatment groups over the entire study.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>DISCUSSION</head><p><s>The results discussed here are from the blinded 24-month follow-up of a phase 3 trial assessing the efficacy and safety of once-daily LCPT MeltDose tablets versus IR-Tac capsules in de novo kidney transplant recipients.</s><s>Consistent with the 12-month results, <ref type="bibr" target="#b40">23</ref> this double-blind double-dummy study in 543 recipients showed that once-daily LCPT was associated with a comparable efficacy and safety profile as IR-Tac at 24 months postrandomization.</s><s>The LCPT group had fewer treatment failures compared to the IR-Tac group over the duration of the study, including early posttransplantation (ie, at 3 months), when there is the greatest risk for rejection; noninferiority was demonstrated at 12 months posttransplantation.</s><s>Lower LCPT doses were able to achieve similar trough levels compared to IR-Tac.</s></p><p><s>]<ref type="bibr" target="#b43">[26]</ref><ref type="bibr" target="#b44">[27]</ref><ref type="bibr" target="#b45">[28]</ref> Lower tacrolimus bioavailability has been observed in females <ref type="bibr" target="#b46">29,</ref><ref type="bibr">30</ref> and African American kidney transplant recipients, largely due to variations in CYP3A5 gene expression <ref type="bibr" target="#b47">31</ref> and polymorphism preponderance (CYP3A5*1 allele). <ref type="bibr" target="#b48">32,</ref><ref type="bibr" target="#b50">33</ref></s><s>The improved bioavailability of LCPT may translate into improved clinical outcomes.</s><s>Although older recipients generally have less acute rejection owing to immunosenescence, <ref type="bibr" target="#b51">34,</ref><ref type="bibr" target="#b52">35</ref> early rejection episodes may be particularly detrimental to long-term clinical outcomes in older recipients. <ref type="bibr" target="#b43">26,</ref><ref type="bibr" target="#b53">36</ref></s><s>It has also been hypothesized that elderly transplant recipients are likely to have a greater degree of variability in tacrolimus pharmacokinetics compared with younger recipients. <ref type="bibr" target="#b54">37</ref></s><s>Thus, it is reasonable to hypothesize that LCPT may be a particularly good option in older receipts due to improved pharmacokinetics and efficacy against rejection.</s><s>The trends observed are consistent with a post hoc analysis performed on pooled 12-month data from de novo and stable kidney  transplant recipients, where significant differences in treatment failure were found in both elderly and black patients for LCPT versus IR-Tac. <ref type="bibr" target="#b55">38</ref></s><s>he incidence of treatment-emergent AEs was similar between both tacrolimus formulations.</s><s>Kidney function was similar between the 2 groups throughout the 24-month study period, as were incidences of malignancy, infections, and NODAT.</s></p><p><s>During this 2-year outpatient therapy period, LCPT patients required lower doses than the IR-Tac group and the difference increased continually over time while trough levels remained similar, indicating the improved absorption by the MeltDose drug delivery technology.</s><s>Absorption (ie, bioavailability) per milligram was significantly greater in the LCPT group versus the IR-Tac group.</s><s>This result is consistent with data from phase 2 studies that demonstrated LCPT is associated with an increase in bioavailability <ref type="bibr" target="#b35">18,</ref><ref type="bibr" target="#b56">39</ref> and a phase 3 conversion study in which the required TDD of LCPT was w20% lower than the preconversion IR-Tac dose, whereas drug trough levels were stable. <ref type="bibr" target="#b39">22</ref></s><s>urrently, LCPT is the only extended-release oncedaily tacrolimus formulation that requires a lower tacrolimus dose to achieve similar exposure levels and demonstrates comparable efficacy to IR-Tac capsules.</s></p><p><s>There are conflicting data for the importance of tacrolimus peak concentrations.</s><s>Although peak concentrations are important for cyclosporine-treated patients, <ref type="bibr" target="#b57">40,</ref><ref type="bibr" target="#b58">41</ref> Undre et al <ref type="bibr" target="#b59">42</ref> reported no association between peak concentration and rejection for tacrolimus-treated patients.</s><s>Instead, overall exposure, as determined by area under the curve, is important for good rejection prophylaxis.</s><s>Conversely, it has been hypothesized that peak calcineurin inhibitor levels may be associated with prevention of rejection. <ref type="bibr" target="#b57">40,</ref><ref type="bibr" target="#b60">43</ref></s><s>owever, results from the present study suggest that this is not the case because LCPT is associated with an w30% lower peak compared to IR-Tac, and it is the achievement of early therapeutic tacrolimus exposure that is likely more important in preventing rejection.</s></p><p><s>An advantage of LCPT tablets is their once-a-day dosing.</s><s>Multiple daily dosing could contribute to lack of adherence, <ref type="bibr" target="#b26">[8]</ref><ref type="bibr" target="#b27">[9]</ref><ref type="bibr" target="#b28">[10]</ref><ref type="bibr" target="#b61">44</ref> and posttransplantation drug regimens are frequently associated with high pill burden. Tra</s><s>splant recipients often have lack of treatment adherence <ref type="bibr" target="#b62">[45]</ref><ref type="bibr" target="#b63">[46]</ref><ref type="bibr">[47]</ref> ; nonadherence is purported to be a major contributor to transplant failure <ref type="bibr" target="#b64">48</ref> and a barrier to improving long-term kidney transplantation outcomes.</s><s>Once-daily tacrolimus has been shown to increase adherence.</s><s><ref type="bibr" target="#b65">49,</ref><ref type="bibr" target="#b66">50</ref> In this double-dummy trial, every patient was assigned to twice-daily dosing in order to not break the blind. Thus,</s><s>it was beyond the scope of this trial to examine whether adherence is increased for LCPT versus IR-Tac twice daily.</s></p><p><s>As for all clinical trials, these results and their generalizability are limited by the patients in a trial having to meet eligibility criteria to participate and might not necessarily be representative of the overall population of de novo kidney transplant recipients.</s><s>In addition, trial participants are in a highly controlled environment and patient behavior (ie, dose adherence and return for clinical follow-up) and that of the treating clinicians might differ outside of the trial conditions, thus influencing clinical outcomes.</s><s>Strengths of this trial include it being double blind with a titratable drug and blinded for 2 years.</s></p><p><s>The MeltDose technology with its improved bioavailability, along with extended drug release, has resulted in a novel once-daily dosing version of tacrolimus.</s><s>Results in this report confirm the benefit of a lower dose to achieve target trough levels.</s><s>This trial offers evidence that LCPT demonstrates comparable efficacy to currently available tacrolimus in de novo kidney transplantation.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>ACKNOWLEDGEMENTS</head><p><s>The members of the Envarsus study group are as follows: United States: Denny, Jason E., MD, Henry Ford Health System, Detroit, MI; Kulkarni, Sanjay, MD, Yale University, New Haven, CT; Hricik, Donald, MD, University Hospitals Case Medical Center, Cleveland, OH; Bresnahan, Barbara A., Medical College of Wisconsin, Milwaukee, WI; Bunnapradist, Suphamai, University of California Los Angeles Medical Center, Los Angeles, CA; El-Sabrout, Rafik A., Westchester Medical Center, Valhalla, NY; Chan, Laurence K., University of Colorado, Denver, CO; Ciancio,  Abbreviations: AE, adverse event; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; IR-Tac, immediate-release tacrolimus, twice-daily; LCPT, extended-release tacrolimus, once daily; LDL, low-density lipoprotein; SAE, serious adverse event.</s></p><p><s>a The opportunistic designation was assigned by the physician.</s><s>b Mostly delayed transplant function.</s></p><p><s>c Calculated as month-24 valuebaseline value for each patient.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head></head><label></label><figDesc><div><p><s>4 6 0.15 [standard error] and 4.5 6 0.22 mg, respectively; P , 0.001; Fig 2).</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Figure 2 .Figure 3 .</head><label>23</label><figDesc><div><p><s>Figure 2. Mean (6 standard error) tacrolimus trough levels and tacrolimus daily dose over the 24-month study period.</s><s>Abbreviations: LCPT, extended-release tacrolimus, once daily; TDD, total daily dose.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>b</head><label></label><figDesc><div><p><s>Percentage was calculated based on persons who participated in the study during this period.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_3"><head>Figure 4 .</head><label>4</label><figDesc><div><p><s>Figure 4. Kaplan-Meier analysis, proportion free of treatment failure over 24 months.</s><s>Abbreviation: LCPT, extended-release tacrolimus, once daily.</s></p></div></figDesc><graphic coords="6,129.03,545.56,335.95,158.23" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_4"><head>a</head><label></label><figDesc><div><p><s>Two-sided Newcombe-Wilson score CIs are presented.</s><s>b P value from 2-sided Fisher exact test.</s><s>c For BPAR severity, mild is acute T-cell-mediated rejection grade IA or IB; moderate is acute T-cell-mediated rejection grade IIA or grade IIB; and severe is acute T-cell-mediated rejection grade III using Banff 2007 criteria.</s><s>BPAR events were based on the central biopsy reading.</s><s>Events occurring prior to or on study day 404 or March 18, 2013, whichever is earlier, are included.</s><s>d P value from Cochran-Mantel-Haenszel test for general association.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head></head><label></label><figDesc><div><p><s>).</s></p></div></figDesc><table><row><cell></cell><cell>PaƟents Enrolled</cell><cell></cell><cell></cell></row><row><cell></cell><cell>N=601</cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell>PaƟents Not Randomized</cell><cell></cell></row><row><cell></cell><cell></cell><cell>N=58</cell><cell></cell></row><row><cell></cell><cell cols="2">PaƟents Randomized</cell><cell></cell></row><row><cell></cell><cell>N=543 (ITT)</cell><cell></cell><cell></cell></row><row><cell></cell><cell>LCPT</cell><cell>Tacrolimus Twice-daily</cell><cell></cell></row><row><cell></cell><cell>N=268</cell><cell>N=275</cell><cell></cell></row><row><cell></cell><cell>Received ≥1 Dose of Study</cell><cell>Received ≥1 Dose of Study</cell><cell></cell></row><row><cell></cell><cell>Drug, N=266</cell><cell>Drug, N=271</cell><cell></cell></row><row><cell>Completed 24 Month Study</cell><cell></cell><cell></cell><cell>Completed 24 Month Study</cell></row><row><cell>Drug Treatment N=195</cell><cell></cell><cell></cell><cell>Drug Treatment N=199</cell></row><row><cell>Reasons for early disconƟnuaƟon: graŌ failure (n=3); AE (n=31); unsaƟsfactory therapeuƟc effect (n=1); paƟent voluntarily disconƟnued</cell><cell>Completed 24 Month Study Period N=253 Reasons for early disconƟnuaƟon: death (n=11); AE (n=1); paƟent voluntarily disconƟnued (n=3)</cell><cell>Completed 24 Month Study Period N=254 Reasons for early disconƟnuaƟon: death (n=13); AE (n=2); lost-to-follow-up (n=3); paƟent voluntarily disconƟnued (n=3)</cell><cell>Reasons for early disconƟnuaƟon: graŌ failure (n=3); rejecƟon (n=1); AE (n=35); unsaƟsfactory therapeuƟc effect (n=2); paƟent voluntarily</cell></row><row><cell>(n=25); physician decision</cell><cell></cell><cell></cell><cell>disconƟnued (n=23);</cell></row><row><cell>(n=4); non-compliance</cell><cell></cell><cell></cell><cell>physician decision (n=4);</cell></row><row><cell>(n=2); other (n=5)</cell><cell></cell><cell></cell><cell>other (n=4)</cell></row></table><note><p><s>Figure 1.</s><s>Patient disposition.</s><s>Abbreviations: AE, adverse event; LCPT, extended-release tacrolimus, once daily.</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 1 .</head><label>1</label><figDesc><div><p><s>Patient Demographics and Baseline Characteristics</s></p></div></figDesc><table><row><cell></cell><cell>LCPT</cell><cell>IR-Tac</cell></row><row><cell></cell><cell>(n 5 268)</cell><cell>(n 5 275)</cell></row><row><cell>Age, y</cell><cell cols="2">44.8 6 13.29 46.9 6 14.26</cell></row><row><cell>Sex</cell><cell></cell><cell></cell></row><row><cell>Male</cell><cell>174 (64.9)</cell><cell>181 (65.8)</cell></row><row><cell>Female</cell><cell>94 (35.1)</cell><cell>94 (34.2)</cell></row><row><cell>Race</cell><cell></cell><cell></cell></row><row><cell>White</cell><cell>203 (75.7)</cell><cell>214 (77.8)</cell></row><row><cell>Black</cell><cell>10 (3.7)</cell><cell>15 (5.5)</cell></row><row><cell>Asian</cell><cell>10 (3.7)</cell><cell>10 (3.6)</cell></row><row><cell>Other</cell><cell>45 (16.8)</cell><cell>36 (13.1)</cell></row><row><cell>Previous transplant</cell><cell>11 (4.1)</cell><cell>11 (4.0)</cell></row><row><cell>Donor type</cell><cell></cell><cell></cell></row><row><cell>Living</cell><cell>135 (50.4)</cell><cell>129 (46.9)</cell></row><row><cell>Deceased</cell><cell>133 (49.6)</cell><cell>145 (52.7)</cell></row><row><cell>Missing</cell><cell>0 (0.0)</cell><cell>1 (0.4)</cell></row><row><cell>PRA, %</cell><cell>1.5 6 5.10</cell><cell>1.5 6 5.98</cell></row><row><cell>PRA , 5%</cell><cell>243 (90.7)</cell><cell>253 (92.0)</cell></row><row><cell>Diabetes at time of transplantation</cell><cell>50 (18.7)</cell><cell>56 (20.4)</cell></row><row><cell>Time from transplantation to</cell><cell cols="2">34.15 6 8.9 34.38 6 9.7</cell></row><row><cell>first study drug dose, h</cell><cell></cell><cell></cell></row></table><note><p><s>Note: Values for categorical variables are given as number (percentage); for continuous variables, as mean 6 standard deviation.</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>Table 2 .</head><label>2</label><figDesc><div><p><s>Efficacy Results During the First and Second 12 Months and Over the 24-Month Study Period</s></p></div></figDesc><table><row><cell></cell><cell>LCPT (n 5 268)</cell><cell>IR-Tac (n 5 275)</cell><cell>Treatment Difference (95% CI) a</cell></row><row><cell>Treatment failure</cell><cell></cell><cell></cell><cell></cell></row><row><cell>0-12 mo</cell><cell>49 (18.3)</cell><cell>54 (19.6)</cell><cell>21.35% (27.94% to 5.27%)</cell></row><row><cell>13-24 mo b</cell><cell>13 (5.1)</cell><cell>21 (8.0)</cell><cell>22.94% (27.38% to 1.42%)</cell></row><row><cell>0-24 mo</cell><cell>62 (23.1)</cell><cell>75 (27.3)</cell><cell>24.14% (211.38% to 3.17%)</cell></row><row><cell>Death</cell><cell></cell><cell></cell><cell></cell></row><row><cell>0-12 mo</cell><cell>8 (3.0)</cell><cell>8 (2.9)</cell><cell>0.08% (23.02% to 3.21%)</cell></row><row><cell>13-24 mo b</cell><cell>3 (1.2)</cell><cell>5 (1.9)</cell><cell>20.74% (23.33% to 1.73%)</cell></row><row><cell>0-24 mo</cell><cell>11 (4.1)</cell><cell>13 (4.7)</cell><cell>20.62% (24.29% to 3.03%)</cell></row><row><cell>Transplant failure</cell><cell></cell><cell></cell><cell></cell></row><row><cell>0-12 mo</cell><cell>9 (3.4)</cell><cell>11 (4.0)</cell><cell>20.64% (24.05% to 2.75%)</cell></row><row><cell>13-24 mo b</cell><cell>2 (0.78)</cell><cell>4 (1.5)</cell><cell>20.75% (23.15% to 1.48%)</cell></row><row><cell>0-24 mo</cell><cell>11 (4.1)</cell><cell>15 (5.5)</cell><cell>21.35% (25.15% to 2.40%)</cell></row><row><cell>Loss to follow-up</cell><cell></cell><cell></cell><cell></cell></row><row><cell>0-12 mo</cell><cell>4 (1.5)</cell><cell>5 (1.8)</cell><cell>20.33% (22.86% to 2.18%)</cell></row><row><cell>13-24 mo b</cell><cell>0 (0.0)</cell><cell>3 (1.2)</cell><cell>NA</cell></row><row><cell>0-24 mo</cell><cell>4 (1.5)</cell><cell>8 (2.9)</cell><cell>21.42% (24.29% to 1.27%)</cell></row><row><cell>BPAR</cell><cell></cell><cell></cell><cell></cell></row><row><cell>0-12 mo</cell><cell>35 (13.1)</cell><cell>37 (13.5)</cell><cell>20.39% (26.14% to 5.38%)</cell></row><row><cell>13-24 mo b</cell><cell>11 (4.3)</cell><cell>13 (5.0)</cell><cell>20.66% (24.50% to 3.16%)</cell></row><row><cell>0-24 mo</cell><cell>46 (17.2)</cell><cell>50 (18.2)</cell><cell>21.02% (27.44% to 5.43%)</cell></row></table><note><p><s>Note: Unless otherwise indicated, values are given as number (percentage).</s><s>The prespecified noninferiority margin was 10%.</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_3"><head>Table 3 .</head><label>3</label><figDesc><div><p><s>Incidence of Clinically Suspected and Treated Acute Rejection Episodes Within 24 Months After Randomization and Severity of First BPAR EpisodeNote: Unless otherwise indicated, values are given as number (percentage).</s><s>Abbreviations: BPAR, biopsy-proven acute rejection; CI, confidence interval; IR-Tac, immediate-release tacrolimus, twice-daily; LCPT, extended-release tacrolimus, once daily.</s></p></div></figDesc><table><row><cell>Parameter</cell><cell>LCPT (n 5 268)</cell><cell>IR-Tac (n 5 275)</cell><cell>LCPT -IR-Tac (95% CI) a</cell><cell>P</cell></row><row><cell>Patients with $1 rejection event</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>0-12 mo</cell><cell>37 (13.8)</cell><cell>43 (15.6)</cell><cell>21.83% (27.81% to 4.18%)</cell><cell>0.6 b</cell></row><row><cell>0-24 mo</cell><cell>46 (17.2)</cell><cell>48 (17.5)</cell><cell>20.29% (26.66% to 6.11%)</cell><cell>0.9 b</cell></row><row><cell>Patients with rejections over 24-mo study</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>1 episode</cell><cell>39 (14.6)</cell><cell>41 (14.9)</cell><cell></cell><cell></cell></row><row><cell>2 episodes</cell><cell>6 (2.2)</cell><cell>6 (2.2)</cell><cell></cell><cell></cell></row><row><cell>3 episodes</cell><cell>1 (0.4)</cell><cell>0 (0.0)</cell><cell></cell><cell></cell></row><row><cell>$4 episodes</cell><cell>0 (0.0)</cell><cell>0 (0.0)</cell><cell></cell><cell></cell></row><row><cell>Severity of first BPAR episode c</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Mild</cell><cell>37 (13.8)</cell><cell>39 (14.2)</cell><cell></cell><cell>0.9 d</cell></row><row><cell>Moderate</cell><cell>8 (3.0)</cell><cell>10 (3.6)</cell><cell></cell><cell></cell></row><row><cell>Severe</cell><cell>1 (0.4)</cell><cell>1 (0.4)</cell><cell></cell><cell></cell></row><row><cell>BPAR treated with polyclonal antibodies</cell><cell>9 (3.4)</cell><cell>12 (4.4)</cell><cell></cell><cell>0.6 b</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_4"><head></head><label></label><figDesc><div><p><s>Forest plot of difference (95% confidence interval) in treatment failure for extended-release tacrolimus, once daily (LCPT) versus twice-daily tacrolimus by patient subgroups and overall.</s></p></div></figDesc><table><row><cell>Age &lt;65 yrs. -2.51% (-10.13%, 5.12%), p=0.539</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Age ≥65 yrs. -25.89% (-45.11%, 0.36%), p=0.067</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Black -23.33% (-52.44%, 14.86%), p=0.414</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Non-black -2.90% (-10.25%, 4.49%), p=0.474</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Female -11.70% (-23.67%, 0.70%), p=0.0915</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Male -0.13% (-9.12%, 8.91%), p&gt;0.999</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>All subjects -4.14% (-11.38%, 3.17%), p=0.278</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>-60%</cell><cell>-40%</cell><cell>-20%</cell><cell>0%</cell><cell>20%</cell><cell>40%</cell><cell>60%</cell></row><row><cell cols="2">In Favor of LCPT</cell><cell></cell><cell></cell><cell cols="2">In Favor of Twice-daily Tacrolimus</cell><cell></cell></row><row><cell>Figure 5.</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table><note><p><s>Am J Kidney Dis.</s><s>2016;67(4):648-659</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_5"><head>Table 4 .</head><label>4</label><figDesc><div><p><s>Summary of AEs, Potentially Clinically Significant Laboratory Values, and Kidney Function</s></p></div></figDesc><table><row><cell></cell><cell>LCPT</cell><cell>IR-Tac</cell></row><row><cell></cell><cell>(n 5 268)</cell><cell>(n 5 275)</cell></row><row><cell>AEs</cell><cell></cell><cell></cell></row><row><cell>No. of AEs</cell><cell>3,842</cell><cell>3,965</cell></row><row><cell>No. of AEs suspected related</cell><cell>493</cell><cell>543</cell></row><row><cell>to study drug</cell><cell></cell><cell></cell></row><row><cell>Patients with $1 AE</cell><cell>263 (98.1)</cell><cell>269 (97.8)</cell></row><row><cell>AEs occurring in $20% of</cell><cell></cell><cell></cell></row><row><cell>overall patients</cell><cell></cell><cell></cell></row><row><cell>Edema peripheral</cell><cell>50 (18.7)</cell><cell>66 (24.0)</cell></row><row><cell>Constipation</cell><cell>51 (19.0)</cell><cell>68 (24.7)</cell></row><row><cell>Diabetes mellitus</cell><cell>55 (20.5)</cell><cell>42 (15.3)</cell></row><row><cell>Tremor</cell><cell>59 (22.0)</cell><cell>51 (18.5)</cell></row><row><cell>Hypertension</cell><cell>71 (26.5)</cell><cell>73 (26.5)</cell></row><row><cell>Anemia</cell><cell>75 (28.0)</cell><cell>84 (30.5)</cell></row><row><cell>Urinary tract infection</cell><cell>81 (30.2)</cell><cell>80 (29.1)</cell></row><row><cell>Diarrhea</cell><cell>91 (34.0)</cell><cell>102 (37.1)</cell></row><row><cell>Malignancies</cell><cell></cell><cell></cell></row><row><cell>0-12 mo</cell><cell>4 (1.5)</cell><cell>3 (1.1)</cell></row><row><cell>0-24 mo</cell><cell>8 (3.0)</cell><cell>8 (2.9)</cell></row><row><cell>Infections</cell><cell></cell><cell></cell></row><row><cell>Any opportunistic a infection</cell><cell></cell><cell></cell></row><row><cell>0-12 mo</cell><cell>92 (34.3)</cell><cell>84 (30.5)</cell></row><row><cell>0-24 mo</cell><cell>110 (41.0)</cell><cell>99 (36.0)</cell></row><row><cell>Cytomegalovirus infection</cell><cell></cell><cell></cell></row><row><cell>0-12 mo</cell><cell>31 (11.6)</cell><cell>25 (9.1)</cell></row><row><cell>0-24 mo</cell><cell>33 (12.3)</cell><cell>29 (10.5)</cell></row><row><cell>BK virus infection</cell><cell></cell><cell></cell></row><row><cell>0-12 mo</cell><cell>24 (9.0)</cell><cell>26 (9.5)</cell></row><row><cell>0-24 mo</cell><cell>32 (11.9)</cell><cell>31 (11.3)</cell></row><row><cell>No. of SAEs</cell><cell>475</cell><cell>519</cell></row><row><cell>Patients with $1 SAE</cell><cell>166 (61.9)</cell><cell>185 (67.3)</cell></row><row><cell>SAEs occurring in $5% of</cell><cell></cell><cell></cell></row><row><cell>overall patients</cell><cell></cell><cell></cell></row><row><cell>Urinary tract infection</cell><cell>9.7%</cell><cell>8.0%</cell></row><row><cell>Kidney transplant rejection</cell><cell>8.6%</cell><cell>12.0%</cell></row><row><cell>Complications of</cell><cell></cell><cell></cell></row><row><cell>transplanted kidney b</cell><cell></cell><cell></cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_6"><head>Table 4 (</head><label>4</label><figDesc><div><p><s>Cont'd).</s><s>Summary of AEs, Potentially Clinically Significant Laboratory Values, and Kidney Function Triglycerides, mg/dL Baseline 98.8 6 3.55 102.7 6 4.39 Month 24 152.6 6 6.69 167.5 6 6.83 Change from baseline 57.2 6 6.54 65.1 6 7.06 Note: Unless otherwise indicated, values are given as number (percentage) or mean 6 standard error.</s><s>Conversion factors for units: cholesterol in mg/dL to mmol/L, 30.02586; creatinine in mg/dL to mmol/L, 388.4; triglycerides in mg/dL to mmol/ L, 30.01129.</s></p></div></figDesc><table><row><cell>LCPT</cell><cell>IR-Tac</cell></row><row><cell>(n 5 268)</cell><cell>(n 5 275)</cell></row></table></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">Am J Kidney Dis. 2016;67(4):648-659</note>
		</body>
		<back>
			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Contributions: Research idea and study design: LR, SB, JMG, KC, JED, HTS, KB; data acquisition: LR, SB, JMG, KC, JED, HTS, KB; data analysis/interpretation: LR, SB, JMG, KC, JED, HTS, KB; statistical analysis: LR, SB, JMG, KC, JED, HTS, KB.</s><s>Each author contributed important intellectual content during manuscript drafting or revision and accepts accountability for the overall work by ensuring that questions pertaining to the accuracy or integrity of any portion of the work are appropriately investigated and resolved.</s><s>All authors take responsibility that this study has been reported honestly, accurately, and transparently; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned and registered have been explained.</s></p><p><s>Peer Review: Evaluated by 2 external peer reviewers, a Statistical Editor, a Co-Editor, and the Editor-in-Chief.</s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title/>
		<idno>mg/dL</idno>
	</analytic>
	<monogr>
		<title level="j">Lipids HDL cholesterol</title>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">University</forename><surname>Gaetano</surname></persName>
		</author>
		<author>
			<persName><surname>Of Miami</surname></persName>
		</author>
		<author>
			<persName><surname>Miami</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Mohamed</forename><forename type="middle">A</forename><surname>Fl; El-Ghoroury</surname></persName>
		</author>
		<author>
			<persName><surname>St</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clair Specialty Physicians</title>
		<editor>Goldstein, Michael J., Mount Sinai Medical Center</editor>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">Robert</forename><forename type="middle">S</forename><surname>Gaston</surname></persName>
		</author>
		<author>
			<persName><surname>University Of Alabama At Birmingham</surname></persName>
		</author>
		<author>
			<persName><surname>Birmingham</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Reginald</forename><forename type="middle">Y</forename><surname>Al; Gohh</surname></persName>
		</author>
		<author>
			<persName><surname>Rhode Island Hospital</surname></persName>
		</author>
		<author>
			<persName><surname>Providence</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Mary</forename><forename type="middle">T</forename><surname>Ri; Killackey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Anne</forename><surname>King</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Virginia</forename><forename type="middle">Commonwealth</forename><surname>University</surname></persName>
		</author>
		<author>
			<persName><surname>Richmond</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Richard</forename><forename type="middle">J</forename><surname>Va; Knight</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">The Methodist Hospital</title>
		<imprint/>
		<respStmt>
			<orgName>Tulane University Medical Center</orgName>
		</respStmt>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">Arputharaj</forename><forename type="middle">H</forename><surname>Kore</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Loma</forename><surname>Linda University Health Care</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Loma</forename><surname>Linda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Debra</forename><forename type="middle">L</forename><surname>Ca; Sudan</surname></persName>
		</author>
		<author>
			<persName><surname>Duke</surname></persName>
		</author>
		<author>
			<persName><surname>Center</surname></persName>
		</author>
		<author>
			<persName><surname>Durham</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Javier</forename><surname>Nc; Chapochnick Friedmann</surname></persName>
		</author>
		<author>
			<persName><surname>Center</surname></persName>
		</author>
		<author>
			<persName><surname>Bronx</surname></persName>
		</author>
		<author>
			<persName><surname>Ny; Mulgaonkar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Shamkant</surname></persName>
		</author>
		<author>
			<persName><forename type="first">John</forename><forename type="middle">D</forename><surname>Pirsch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Madison</forename><surname>University Of Wisconsin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Heidi</forename><forename type="middle">M</forename><surname>Schaefer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Bruce</forename><forename type="middle">E</forename><surname>Gelb</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Saint Barnabas Medical Center</title>
		<imprint/>
		<respStmt>
			<orgName>Vanderbilt University Medical Center ; New York University Medical Center</orgName>
		</respStmt>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Central Pennsylvania Transplant Foundation</title>
		<author>
			<persName><forename type="first">Karin</forename><forename type="middle">A</forename><surname>True</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Mary</forename><forename type="middle">M ;</forename><surname>; ; Waybill</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Joshua</forename><forename type="middle">H</forename><surname>Wolf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Atlanta</forename><surname>Piedmont Healthcare Research Institute</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Beverley</forename><forename type="middle">L</forename><surname>Ga; Ketel</surname></persName>
		</author>
		<author>
			<persName><surname>Associates</surname></persName>
		</author>
		<author>
			<persName><surname>Peoria</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Robert</forename><forename type="middle">C</forename><surname>Harland</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Carolina</forename><surname>East</surname></persName>
		</author>
		<author>
			<persName><surname>University</surname></persName>
		</author>
		<author>
			<persName><surname>Greenville</surname></persName>
		</author>
		<author>
			<persName><surname>Nc; Shihab</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Fuad</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Salt</forename><surname>University Of Utah</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><forename type="middle">T</forename><surname>Lake City</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Elisabeth</forename><surname>France: Cassuto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Nice; Le</forename><surname>Archet</surname></persName>
		</author>
		<author>
			<persName><surname>Meur</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">Grinyó, Josep Maria, Hospital Universitari De Bellvitge, Cataluña; Puig, Jose, Hospital del Mar</title>
				<meeting><address><addrLine>Chicago, IL; Harrisburg, PA; Yannick, Hôpital de La Cavale Blanche, Brest; Rostaing, Lionel, Hôpital de Rangueil, Toulouse; Mariat, Christophe, Association SRT, Saint-Etienne. Spain; Barcelona; Seron, Daniel; Klemens, Charitè Campus Mitte, Berlin</addrLine></address></meeting>
		<imprint/>
		<respStmt>
			<orgName>University of North Carolina at Chapel Hill, Chapel Hill, NC; West-Thielke, Patricia M., University of Illinois at Chicago ; Hospital Vall D&apos;Hebron Barcelona. Italy: Tisone, Giuseppe, Fondazione PTV Policlinico, Roma. Poland: Ciechanowski, Kazimierz, Samodzielny Publiczny Szpital Kliniczny, Szczecin; Foroncewicz, Bartosz, Szpital Kliniczny Dzieciatka Jezus, Warszawa; Wlodarczyk, Zbigniew, Szpital Uniwersytecki im. Dr A. Jurasza, Bydgoszcz. Germany: Budde</orgName>
		</respStmt>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Mancilla Urrea, Eduardo, Instituto Nacional de Cardiologia</title>
		<author>
			<persName><forename type="first">Oliver</forename><surname>Witzke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Universitätsklinikum</forename><surname>Essen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Essen</forename><surname>Mexico: Mondragon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Guillermo</forename><forename type="middle">A</forename><surname>Instituto Mexicano De Transplantes</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Dr. Ignacio Chavez</title>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<monogr>
		<title level="m" type="main">Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran</title>
		<author>
			<persName><forename type="first">Alberu</forename><surname>Gomez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Josefina</forename></persName>
		</author>
		<imprint>
			<pubPlace>Mexico City</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">Reyes</forename><surname>Acevedo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Centenario</forename><surname>Rafael</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Miguel</forename><surname>Hospital</surname></persName>
		</author>
		<author>
			<persName><surname>Hidalgo</surname></persName>
		</author>
		<imprint>
			<pubPlace>Aguascalientes. Argentina: Rial, Maria del Carmen, Instituto de Nefrología, Buenos Aires</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<monogr>
		<author>
			<persName><forename type="first">Pablo</forename><forename type="middle">A</forename><surname>Novoa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Cordoba</forename><surname>Cordoba</surname></persName>
		</author>
		<author>
			<persName><surname>Brazil</surname></persName>
		</author>
		<author>
			<persName><surname>Silva</surname><genName>Jr</genName></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Helio</surname></persName>
		</author>
		<title level="m">Hospital do Rim e Hipertensão</title>
				<meeting><address><addrLine>São Paulo</addrLine></address></meeting>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">Valter</forename><forename type="middle">D</forename><surname>Garcia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Irmandade</forename><surname>Santa</surname></persName>
		</author>
		<imprint>
			<pubPlace>Rio Grande do Sul</pubPlace>
		</imprint>
		<respStmt>
			<orgName>Casa de Misericórdia de Porto Alegre</orgName>
		</respStmt>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<monogr>
		<title level="m" type="main">Hospital Geral de Bonsucesso</title>
		<author>
			<persName><forename type="first">Deise</forename><forename type="middle">D</forename><surname>Carvalho</surname></persName>
		</author>
		<imprint>
			<pubPlace>Rio de Janeiro</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<monogr>
		<title level="m" type="main">Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto</title>
		<author>
			<persName><forename type="first">Santamaria</forename><surname>Saber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Luciana</forename><forename type="middle">T</forename></persName>
		</author>
		<imprint>
			<pubPlace>Ribeirão Preto</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">Fabiana</forename><forename type="middle">L</forename><surname>Contieri</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curitiba</title>
		<imprint/>
		<respStmt>
			<orgName>Hospital Universitário Evangélico de Curitiba</orgName>
		</respStmt>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">Roberto</forename><forename type="middle">C</forename><surname>Manfro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Rio</forename><surname>Hospital De Clínicas De Porto Alegre</surname></persName>
		</author>
		<author>
			<persName><surname>Grande</surname></persName>
		</author>
		<author>
			<persName><surname>Sul</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Australia: Kanellis</title>
		<imprint>
			<publisher>Eris</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<monogr>
		<title/>
		<author>
			<persName><surname>O'connell</surname></persName>
		</author>
		<imprint>
			<pubPlace>Philip, Westmead Hospital, Westmead, NSW</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">Peter</forename><surname>Hughes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Royal</forename><forename type="middle">Melbourne</forename><surname>Hospital</surname></persName>
		</author>
		<author>
			<persName><surname>Parkville</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Graeme</forename><surname>Vic; Russ</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Royal</forename><forename type="middle">Adelaide</forename><surname>Hospital</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Sa</forename><forename type="middle">New</forename><surname>Zealand</surname></persName>
		</author>
		<imprint>
			<publisher>Pidgeon</publisher>
			<pubPlace>Grant B., Wellington Hospital, Wellington</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Support: Veloxis Pharmaceuticals provided funding for this manuscript, and contributed to study design. Collection, analysis, and interpretation of data; writing the report; and the decision to submit the report for publication were done by the authors. Kristin Kistler, PhD, from Evidera, provided medical writing support</title>
		<author>
			<persName><forename type="first">Ian</forename><forename type="middle">D</forename><surname>Dittmer</surname></persName>
		</author>
		<author>
			<persName><surname>Auckland City</surname></persName>
		</author>
		<author>
			<persName><surname>Hospital</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Auckland</forename><surname>Grafton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Terence</forename><surname>Singapore: Kee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Anantharaman</forename><surname>Vathsala</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">Alexion, and Veloxis Pharma and on advisory board of Chiesi. Dr Bunnapradist: grant/research support from Veloxis, BMS, Novartis, and Genentech and on advisory board of Astellas and Alexion</title>
				<meeting><address><addrLine>Vienna, Austria; Seattle, WA; San Francisco, CA; Madrid, Spain; PA; Novartis, Pfizer, Roche, Siemens, Chiesi, Fresenius</addrLine></address></meeting>
		<imprint>
			<date type="published" when="2013-05-11">September 8-11, 2013. May 18-22, 2013. July 26-31, 2014. October 17-19, 2014. 2014. November 11-16, 2014. March 13-17, 2015</date>
		</imprint>
		<respStmt>
			<orgName>National University of Singapore. Serbia: Naumovic, Radomir, Clinical Center of Serbia, Belgrade; Mitic, Igor, Clinical Centre of Vojvodina, Novi Sad. Central reader: Parmjeet Randhawa, MD, University of Pittsburgh Medical Center</orgName>
		</respStmt>
	</monogr>
	<note>Financial Disclosure: Dr Budde: research funds and/or honoraria from AiCuris, Astellas, Bristol-Myers Squibb, Hexal, Effimune Pharma. Dr Ciechanowski: participated in clinical trials with Veloxis as a principal investigator. Dr Denny: grant/research support from and on advisory board of Veloxis</note>
</biblStruct>

<biblStruct xml:id="b17">
	<monogr>
		<title level="m" type="main">Dr Silva Jr: participated in this clinical trial with Veloxis as a principal investigator and has received honoraria from Novartis and Pfizer</title>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<monogr>
		<title level="m" type="main">Dr Silva Jr&apos;s institution has received research grants from Novartis</title>
		<author>
			<persName><surname>Bms</surname></persName>
		</author>
		<author>
			<persName><surname>Pfizer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Teraclone</forename><surname>Roche</surname></persName>
		</author>
		<author>
			<persName><surname>Dr Rostaing</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Department of Health and Human Services, Health Resources and Services Administration</title>
	</analytic>
	<monogr>
		<title level="j">Organ Procurement and Transplantation Network</title>
		<imprint>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note>OPTN) and Scientific Registry of Transplant Recipients (SRTR)</note>
</biblStruct>

<biblStruct xml:id="b20">
	<monogr>
		<ptr target="http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm181006.pdf.Ac-cessed" />
		<title level="m">US Food and Drug Administration. Draft Guidance on Tacrolimus</title>
				<imprint>
			<date type="published" when="2014-07-02">July 2, 2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Zaltzman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Lai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">Z</forename><surname>Schulz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K-H</forename><surname>Moon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">Z</forename><surname>Cherney</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">A randomized cross-over comparison of short-term exposure of oncedaily extended release tacrolimus and twice-daily tacrolimus on renal function in healthy volunteers</title>
	</analytic>
	<monogr>
		<title level="j">Transpl Int</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="1294" to="1302" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Neurotoxicity of calcineurin inhibitors: impact and clinical management</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">O</forename><surname>Bechstein</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Transpl Int</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="313" to="326" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Neurologic complications of FK 506</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">H</forename><surname>Eidelman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Abu-Elmagd</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Wilson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Transplant Proc</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="3175" to="3178" />
			<date type="published" when="1991">1991</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">in transplant patients with intolerance to tacrolimus</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Abouljoud</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Msa</forename><surname>Kumar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">L</forename><surname>Brayman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Emre</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Bynon</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Kidney Dis</title>
		<imprint>
			<biblScope unit="volume">67</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="168" to="172" />
			<date type="published" when="2002">2016. 2002</date>
		</imprint>
	</monogr>
	<note>Clin Transplant</note>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">The effect of prescribed daily dose frequency on patient medication compliance</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Eisen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">K</forename><surname>Miller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">S</forename><surname>Woodward</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Spitznagel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">R</forename><surname>Przybeck</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arch Intern Med</title>
		<imprint>
			<biblScope unit="volume">150</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="1881" to="1884" />
			<date type="published" when="1990">1990</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">A systematic review of the associations between dose regimens and medication compliance</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Claxton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Cramer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Pierce</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Ther</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="1296" to="1310" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Effect of medication dosing frequency on adherence in chronic diseases</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Saini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Schoenfeld</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Kaulback</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Dubinsky</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Manag Care</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="e22" to="e33" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Factors contributing to acute rejection in renal transplantation: the role of noncompliance</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">E</forename><surname>Morrissey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Reinert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Yango</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Gautam</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Monaco</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Gohh</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Transplant Proc</title>
		<imprint>
			<biblScope unit="volume">37</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="2044" to="2047" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">US Food and Drug Administration. Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a</title>
		<author>
			<persName><forename type="first">T</forename><surname>Michelon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Dominguez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Losekan</surname></persName>
		</author>
		<ptr target="http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070246.pdf.Ac-cessed" />
	</analytic>
	<monogr>
		<title level="j">Biopharmaceutics Classification System</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="3031" to="3032" />
			<date type="published" when="1999-05">1999. May 2007. July 2. 2014</date>
		</imprint>
	</monogr>
	<note>Transplant Proc</note>
</biblStruct>

<biblStruct xml:id="b31">
	<monogr>
		<title level="m" type="main">Improved bioavailability of MELTDOSE once-daily formulation of tacrolimus (LCP-Tacro) with controlled agglomeration allows for consistent absorption over 24 hrs: a scintigraphic and pharmacokinetic evaluation. Presented at</title>
		<author>
			<persName><forename type="first">V</forename><surname>Nigro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Glicklich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Weinberg</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2013">May 18-22. 2013</date>
			<publisher>American Transplant Congress</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">A</forename><surname>Seattle</surname></persName>
		</author>
		<imprint>
			<date type="published" when="1034">Abstract B1034</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Flexible dosing of oncedaily LCP-Tacro tablets: morning vs. evening randomized crossover chronopharmacokinetic study</title>
		<author>
			<persName><forename type="first">V</forename><surname>Nigro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Glicklich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Weinberg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">Presented at: AST/ESOT Joint Meeting; October</title>
				<meeting><address><addrLine>Nice, France</addrLine></address></meeting>
		<imprint>
			<date type="published" when="2012">2012</date>
			<biblScope unit="page" from="12" to="14" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<monogr>
		<title level="m" type="main">ASTAGRAF XL tacrolimus capsule, coated, extended release</title>
		<imprint>
			<date type="published" when="2015">2015</date>
			<publisher>Astellas Pharma US, Inc</publisher>
			<pubPlace>Northbrook, IL</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">A phase 2 randomized study of the pharmacokinetics, safety and efficacy of LCP-Tacro tablets once-a-day vs Prograf capsules twicea-day in de novo kidney transplants</title>
		<author>
			<persName><forename type="first">R</forename><surname>Alloway</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Mulgaonkar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Ueda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Cohen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Kaplan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Transplant</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page">355</biblScope>
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
	<note>suppl</note>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">Conversion from twice-daily tacrolimus capsules to once-daily extended-release tacrolimus (LCPT): a phase 2 trial of stable renal transplant recipients</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">O</forename><surname>Gaber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">R</forename><surname>Alloway</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Bodziak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Kaplan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Bunnapradist</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Transplantation</title>
		<imprint>
			<biblScope unit="volume">96</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="191" to="197" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">Conversion from twice-daily tacrolimus capsules to once-daily extended-release tacrolimus (LCPT): phase II trial of stable liver transplant recipients</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">R</forename><surname>Alloway</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">E</forename><surname>Eckhoff</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Washburn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">W</forename><surname>Teperman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Liver Transpl</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="564" to="575" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">A phase 2b, open-label, multicenter, prospective, randomized study to compare the pharmacokinetics and safety of LCP-TacroÔ tablets once-aday to PrografÒ capsules twice-a-day in de novo liver transplant patients</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Dubay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">R</forename><surname>Alloway</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">E</forename><surname>Alsina</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Liver Transpl</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page">S14</biblScope>
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
	<note>suppl</note>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">Conversion from twice-daily tacrolimus to once-daily extended release tacrolimus (LCPT): the phase III randomized MELT Trial</title>
		<author>
			<persName><forename type="first">S</forename><surname>Bunnapradist</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Ciechanowski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>West-Thielke</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Transplant</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="760" to="769" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">Once daily LCP-Tacro MeltDoseÒ tacrolimus vs. twice daily tacrolimus in de novo kidney transplants: one-year results of phase 3, double-blind, randomized trial</title>
		<author>
			<persName><forename type="first">K</forename><surname>Budde</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Bunnapradist</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Grinyo</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Transplant</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="2796" to="2806" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">Outcomes in African American kidney transplant patients receiving tacrolimus and mycophenolic acid immunosuppression</title>
		<author>
			<persName><forename type="first">M</forename><surname>Narayanan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Pankewycz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>El-Ghoroury</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Transplantation</title>
		<imprint>
			<biblScope unit="volume">95</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="566" to="572" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">Long-term outcomes in African American kidney transplant recipients under contemporary immunosuppression: a four-yr analysis of the Mycophenolic acid Observational REnal transplant (MORE) study</title>
		<author>
			<persName><forename type="first">M</forename><surname>Narayanan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Pankewycz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Shihab</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Wiland</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Mccague</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Chan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Transplant</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="184" to="191" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main">Clinical outcomes in elderly kidney transplant recipients are related to acute rejection episodes rather than pretransplant comorbidity</title>
		<author>
			<persName><forename type="first">K</forename><surname>Heldal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Hartmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Leivestad</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Transplantation</title>
		<imprint>
			<biblScope unit="volume">87</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="1045" to="1051" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main">Understanding the influence of ethnicity and socioeconomic factors on graft and patient survival after kidney transplantation</title>
		<author>
			<persName><forename type="first">M</forename><surname>Laging</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Kal-Van Gestel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Van De Wetering</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">N</forename><surname>Ijzermans</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Weimar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">I</forename><surname>Roodnat</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Transplantation</title>
		<imprint>
			<biblScope unit="volume">98</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="974" to="978" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main">Mortality after kidney transplant failure: the impact of non-immunologic factors</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Gill</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Abichandani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">T</forename><surname>Kausz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Bjg</forename><surname>Pereira</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Kidney Int</title>
		<imprint>
			<biblScope unit="volume">62</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="1875" to="1883" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main">A randomized, crossover pharmacokinetic study comparing generic tacrolimus vs. the reference formulation in subpopulations of kidney transplant patients</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">D</forename><surname>Bloom</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Trofe-Clark</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Wiland</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Rr ; R</forename><surname>Alloway</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Mikov</surname></persName>
		</author>
		<author>
			<persName><surname>Paunovi C G</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Transplant</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="23" to="31" />
			<date type="published" when="2011">2013. 2011</date>
		</imprint>
	</monogr>
	<note>Gend Med</note>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main">Inherent sexdependent regulation of human hepatic CYP3A5</title>
		<author>
			<persName><forename type="first">C</forename><surname>Thangavel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Boopathi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">H</forename><surname>Shapiro</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Pharmacol</title>
		<imprint>
			<biblScope unit="volume">168</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="988" to="1000" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b48">
	<monogr>
		<title level="m" type="main">Pharmacokinetics of immunosuppressants: a perspective on ethnic differences</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">L</forename><surname>Dirks</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Huth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">R</forename><surname>Yates</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Meibohm</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b49">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j">Int J Clin Pharmacol Ther</title>
		<imprint>
			<biblScope unit="volume">42</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="701" to="718" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b50">
	<analytic>
		<title level="a" type="main">The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation</title>
		<author>
			<persName><forename type="first">Iam</forename><surname>Macphee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Fredericks</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Tai</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Transplant</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="914" to="919" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b51">
	<analytic>
		<title level="a" type="main">Aging of the innate immune system: an update</title>
		<author>
			<persName><forename type="first">S</forename><surname>Mahbub</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Brubaker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">J</forename><surname>Kovacs</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Immunol Rev</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="104" to="115" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b52">
	<analytic>
		<title level="a" type="main">The combination of donor and recipient age is critical in determining host immunoresponsiveness and renal transplant outcome</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">G</forename><surname>Tullius</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Tran</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Guleria</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">K</forename><surname>Malek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">L</forename><surname>Tilney</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Milford</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Surg</title>
		<imprint>
			<biblScope unit="volume">252</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="662" to="674" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b53">
	<analytic>
		<title level="a" type="main">The impact of age on rejection in kidney transplantation</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename><surname>De Fijter</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Drugs Aging</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="433" to="449" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b54">
	<analytic>
		<title level="a" type="main">Pharmacokinetic considerations relating to tacrolimus dosing in the elderly</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">E</forename><surname>Staatz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">E</forename><surname>Tett</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Drugs Aging</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="541" to="557" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b55">
	<monogr>
		<title level="m" type="main">Lower treatment failures in blacks and older denovo and stable kidney transplant recipients treated with Envarsus once-daily MeltDose tablets vs. twice-daily Prograf capsules: a pooled subgroup analysis of two phase 3 trials. Presented at: World Transplant Congress</title>
		<author>
			<persName><forename type="first">S</forename><surname>Bunnapradist</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Alloway</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>West-Thielke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Denny</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Mulgaonkar</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2014">July 26-31. 2014</date>
			<pubPlace>San Francisco, CA</pubPlace>
		</imprint>
	</monogr>
	<note>Abstract 50</note>
</biblStruct>

<biblStruct xml:id="b56">
	<analytic>
		<title level="a" type="main">A phase 2b, open-label, multi-center, prospective, randomized study to compare the pharmacokinetics and safety of LCP-TacroÔ tablets once-a-day to PrografÒ capsules twice-a-day in de novo kidney transplant patients</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">R</forename><surname>Alloway</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Mulgaonkar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">D</forename><surname>Bowers</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Transplant</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page">414</biblScope>
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b57">
	<monogr>
		<title level="m" type="main">Peak cyclosporine levels (C max ) correlate with freedom from liver graft rejection: results of a prospective, randomized comparison of Neoral and Sandimmune for liver transplantation (NOF-8)1,2. Transplantation</title>
		<author>
			<persName><forename type="first">D</forename><surname>Grant</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Kneteman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Tchervenkov</surname></persName>
		</author>
		<imprint>
			<date type="published" when="1999">1999</date>
			<biblScope unit="volume">67</biblScope>
			<biblScope unit="page" from="1133" to="1137" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b58">
	<analytic>
		<title level="a" type="main">Use of Neoral C2 monitoring: a European consensus</title>
		<author>
			<persName><forename type="first">B</forename><surname>Nashan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Bock</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J-L</forename><surname>Bosmans</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Transpl Int</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="768" to="778" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b59">
	<analytic>
		<title level="a" type="main">Low systemic exposure to tacrolimus correlates with acute rejection</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">A</forename><surname>Undre</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Van Hooff</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Christiaans</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Transplant Proc</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="issue">1-2</biblScope>
			<biblScope unit="page" from="296" to="298" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b60">
	<analytic>
		<title level="a" type="main">The noninferiority trial: don&apos;t don&apos;t do it</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">R</forename><surname>Srinivas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Kaplan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Meier-Kriesche</forename><surname>Hu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Transplant</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="2571" to="2573" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b61">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">I</forename><surname>Feldman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Hackett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Bilker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">L</forename><surname>Strom</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b62">
	<analytic>
		<title level="a" type="main">Nonadherent behaviors after solid organ transplantation</title>
		<author>
			<persName><forename type="first">G</forename><surname>Germani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Lazzaro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Gnoato</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Transplant Proc</title>
		<imprint>
			<biblScope unit="volume">43</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="318" to="323" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b63">
	<analytic>
		<title level="a" type="main">Laederach-Hofmann K, Bunzel B. Noncompliance in organ transplant recipients: a literature review</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Chisholm</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Gen Hosp Psychiatry</title>
		<imprint>
			<biblScope unit="volume">62</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="412" to="424" />
			<date type="published" when="2000">2002. 2000</date>
		</imprint>
	</monogr>
	<note>Drugs</note>
</biblStruct>

<biblStruct xml:id="b64">
	<analytic>
		<title level="a" type="main">Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence</title>
		<author>
			<persName><forename type="first">J</forename><surname>Sellarés</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">G</forename><surname>De Freitas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Mengel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Transplant</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="388" to="399" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b65">
	<analytic>
		<title level="a" type="main">Improved adherence to tacrolimus once-daily formulation in renal recipients: a randomized controlled trial using electronic monitoring</title>
		<author>
			<persName><forename type="first">Drj</forename><surname>Kuypers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">C</forename><surname>Peeters</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Sennesael</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Transplantation</title>
		<imprint>
			<biblScope unit="volume">95</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="333" to="340" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b66">
	<analytic>
		<title level="a" type="main">Increased adherence eight months after switch from twice daily calcineurin inhibitor based treatment to once daily modified released tacrolimus in heart transplantation</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">O</forename><surname>Doesch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Mueller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Akyol</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Drug Des Dev Ther</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page" from="1253" to="1258" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
